Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER (CORAL) clinical trial for treatment of chronic cough in patients with IPF; phase 2a Refractory Chronic Cough Improvement Via NAL ER (RIVER) clinical trial for reducing chronic cough in RCC patients; phase 2 clinical trial in patients with pruritus; phase 2b/3 clinical trial in patients with prurigo nodularis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut. more
Time Frame | TRVI | Sector | S&P500 |
---|---|---|---|
1-Week Return | 67.91% | -3.39% | 0.2% |
1-Month Return | 59.57% | -1.92% | 2.72% |
3-Month Return | 35.14% | -10.54% | 7.31% |
6-Month Return | 66.36% | -4.47% | 10.44% |
1-Year Return | 248.84% | 4.06% | 27.53% |
3-Year Return | 548.41% | 0.94% | 30.88% |
5-Year Return | 25% | 36.67% | 89.21% |
10-Year Return | -42.97% | 102.87% | 199.95% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Cost of Revenue | 39.00K | 47.00K | 50.00K | 43.00K | 123.00K | [{"date":"2019-12-31","value":31.71,"profit":true},{"date":"2020-12-31","value":38.21,"profit":true},{"date":"2021-12-31","value":40.65,"profit":true},{"date":"2022-12-31","value":34.96,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Profit | (39.00K) | (47.00K) | (50.00K) | (43.00K) | (123.00K) | [{"date":"2019-12-31","value":-3900000,"profit":false},{"date":"2020-12-31","value":-4700000,"profit":false},{"date":"2021-12-31","value":-5000000,"profit":false},{"date":"2022-12-31","value":-4300000,"profit":false},{"date":"2023-12-31","value":-12300000,"profit":false}] |
Gross Margin | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Operating Expenses | 26.64M | 32.49M | 32.48M | 29.91M | 33.92M | [{"date":"2019-12-31","value":78.55,"profit":true},{"date":"2020-12-31","value":95.77,"profit":true},{"date":"2021-12-31","value":95.73,"profit":true},{"date":"2022-12-31","value":88.16,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (26.64M) | (32.49M) | (32.48M) | (29.91M) | (33.92M) | [{"date":"2019-12-31","value":-2664500000,"profit":false},{"date":"2020-12-31","value":-3248900000,"profit":false},{"date":"2021-12-31","value":-3247600000,"profit":false},{"date":"2022-12-31","value":-2990700000,"profit":false},{"date":"2023-12-31","value":-3392300000,"profit":false}] |
Total Non-Operating Income/Expense | 1.37M | (565.00K) | (2.68M) | 1.30M | 8.89M | [{"date":"2019-12-31","value":15.39,"profit":true},{"date":"2020-12-31","value":-6.35,"profit":false},{"date":"2021-12-31","value":-30.1,"profit":false},{"date":"2022-12-31","value":14.57,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Pre-Tax Income | (26.07M) | (32.78M) | (33.96M) | (29.19M) | (29.10M) | [{"date":"2019-12-31","value":-2606800000,"profit":false},{"date":"2020-12-31","value":-3277600000,"profit":false},{"date":"2021-12-31","value":-3396100000,"profit":false},{"date":"2022-12-31","value":-2918800000,"profit":false},{"date":"2023-12-31","value":-2909700000,"profit":false}] |
Income Taxes | (18.00K) | (18.00K) | (21.00K) | (36.00K) | (32.00K) | [{"date":"2019-12-31","value":-1800000,"profit":false},{"date":"2020-12-31","value":-1800000,"profit":false},{"date":"2021-12-31","value":-2100000,"profit":false},{"date":"2022-12-31","value":-3600000,"profit":false},{"date":"2023-12-31","value":-3200000,"profit":false}] |
Income After Taxes | (26.05M) | (32.76M) | (33.94M) | (29.15M) | (29.07M) | [{"date":"2019-12-31","value":-2605000000,"profit":false},{"date":"2020-12-31","value":-3275800000,"profit":false},{"date":"2021-12-31","value":-3394000000,"profit":false},{"date":"2022-12-31","value":-2915200000,"profit":false},{"date":"2023-12-31","value":-2906500000,"profit":false}] |
Income From Continuous Operations | (26.05M) | (32.76M) | (33.94M) | (29.15M) | (26.75M) | [{"date":"2019-12-31","value":-2605000000,"profit":false},{"date":"2020-12-31","value":-3275800000,"profit":false},{"date":"2021-12-31","value":-3394000000,"profit":false},{"date":"2022-12-31","value":-2915200000,"profit":false},{"date":"2023-12-31","value":-2674900000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (26.05M) | (32.76M) | (33.94M) | (29.15M) | (29.07M) | [{"date":"2019-12-31","value":-2605000000,"profit":false},{"date":"2020-12-31","value":-3275800000,"profit":false},{"date":"2021-12-31","value":-3394000000,"profit":false},{"date":"2022-12-31","value":-2915200000,"profit":false},{"date":"2023-12-31","value":-2906500000,"profit":false}] |
EPS (Diluted) | (15.26) | (1.81) | (1.52) | (0.56) | (0.29) | [{"date":"2019-12-31","value":-1526,"profit":false},{"date":"2020-12-31","value":-181,"profit":false},{"date":"2021-12-31","value":-152,"profit":false},{"date":"2022-12-31","value":-56,"profit":false},{"date":"2023-12-31","value":-29,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
TRVI | |
---|---|
Cash Ratio | 7.18 |
Current Ratio | 7.38 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
TRVI | |
---|---|
ROA (LTM) | -36.57% |
ROE (LTM) | -59.65% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
TRVI | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.14 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.86 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
TRVI | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 0.00 |
P/B | 5.53 |
Price/FCF | NM |
EV/R | 0.00 |
EV/Ebitda | NM |
Trevi Therapeutics Inc (TRVI) share price today is $4.32
Yes, Indians can buy shares of Trevi Therapeutics Inc (TRVI) on Vested. To buy Trevi Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in TRVI stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Trevi Therapeutics Inc (TRVI) via the Vested app. You can start investing in Trevi Therapeutics Inc (TRVI) with a minimum investment of $1.
You can invest in shares of Trevi Therapeutics Inc (TRVI) via Vested in three simple steps:
The 52-week high price of Trevi Therapeutics Inc (TRVI) is $4.6. The 52-week low price of Trevi Therapeutics Inc (TRVI) is $1.26.
The price-to-earnings (P/E) ratio of Trevi Therapeutics Inc (TRVI) is
The price-to-book (P/B) ratio of Trevi Therapeutics Inc (TRVI) is 5.53
The dividend yield of Trevi Therapeutics Inc (TRVI) is 0.00%
The market capitalization of Trevi Therapeutics Inc (TRVI) is $325.91M
The stock symbol (or ticker) of Trevi Therapeutics Inc is TRVI